Hydroxylases as therapeutic targets in inflammatory bowel disease.
about
The impact of hypoxia on intestinal epithelial cell functions: consequences for invasion by bacterial pathogensOxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal CancerRegulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways.Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn's disease/infectious colitis and healthy controlsTherapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis.Hypoxia-sensitive pathways in inflammation-driven fibrosis.The role of hypoxia in inflammatory disease (review)Oxygen sensing in intestinal mucosal inflammation.Hypoxia-dependent regulation of inflammatory pathways in immune cellsHypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function.Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study.Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected].Regulation of immunity and inflammation by hypoxia in immunological niches.Hypoxia-sensitive pathways in intestinal inflammation.Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.The PHD1 oxygen sensor in health and disease.Activation of hypoxia-inducible factor 1 attenuates periapical inflammation and bone loss.
P2860
Q26752794-12B438A2-C539-4643-ACD8-8DF04F8FCF51Q28073745-92243CA0-1441-44F4-8383-B0169EB8BB94Q37319845-F340D2F6-0B95-4AA2-A8FE-189599DFDFA4Q37347989-8CB33D10-F67D-4251-BF4C-42BC9CD3C017Q37538086-6D3E6808-6656-4FAB-917F-35397375982FQ38258327-F25D8E80-33AF-4254-B938-B0170CD35927Q38334119-8770E3F8-46F1-4E0F-AEDD-09D038A0E859Q38553186-D055EB78-7DFD-4F22-A107-9B02603990DCQ38907502-CDA3AA87-9749-4D93-AF19-295BDA573E1BQ39277299-8563468E-31E5-40C7-B71C-909409BBBE8AQ41112476-8E9E46E0-3B0D-4059-847B-55AEF4D6EC50Q46623958-A455137C-8159-48A4-BCFC-13F038628D62Q47708732-C241C072-0077-43E5-B69C-649995F5AF43Q48346681-686BD0B8-8909-46A8-B553-E082EF2F1562Q49130305-24C9FC5C-D7C2-48F3-9E7E-8B8475676967Q50050250-8450B85A-13F0-414D-8C0D-3CFE4558AC9BQ54236077-F655B764-3A7C-4A79-BDAF-D786A4A46499
P2860
Hydroxylases as therapeutic targets in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Hydroxylases as therapeutic targets in inflammatory bowel disease.
@en
type
label
Hydroxylases as therapeutic targets in inflammatory bowel disease.
@en
prefLabel
Hydroxylases as therapeutic targets in inflammatory bowel disease.
@en
P2093
P2860
P50
P356
P1476
Hydroxylases as therapeutic targets in inflammatory bowel disease
@en
P2093
Cormac T Taylor
Eoin P Cummins
Glen A Doherty
P2860
P2888
P304
P356
10.1038/LABINVEST.2013.9
P577
2013-02-18T00:00:00Z
P5875
P6179
1028704264